ZYUS issued 111,110 units at C$0.45 each for gross proceeds of C$50,000; company insiders purchased all units. Combined proceeds from the first and second tranches are approximately $0.25M.
Material Details
Context by AI Analyst
This is a financing update for a clinical-stage company, not a clinical or commercial milestone. The next catalyst is whether the expected additional tranche closes and how much it raises.
Based on the original press release from ZYUS Life Sciences Corporation distributed by PR Newswire.
